AHB(SH:688639) Shenwan Hongyuan Securities·2026-03-24 02:12Investment Rating - The report maintains a rating of "Outperform" for the company [6] Core Insights - The company reported a revenue of 2.862 billion yuan for 2025, reflecting a year-over-year growth of 31.4%, but the net profit attributable to shareholders decreased by 30.1% to 132 million yuan [4][5] - The decline in profitability is attributed to falling prices of products like valine, increased operational costs, and foreign exchange losses due to a significant portion of revenue (39%) coming from overseas [6] - The company is transitioning from amino acids to new materials, with a focus on PDO (1,3-Propanediol) as a key product for future growth, aiming to break the DuPont monopoly in the market [6] Financial Data Summary - For 2025, the company achieved a total revenue of 28.62 billion yuan, with a gross margin of 21.3% [4][5] - The projected revenues for the next few years are as follows: 3.406 billion yuan in 2026, 4.074 billion yuan in 2027, and 4.840 billion yuan in 2028, with corresponding net profits expected to be 233 million yuan, 349 million yuan, and 491 million yuan respectively [5][7] - The company's return on equity (ROE) is projected to improve from 5.0% in 2025 to 14.0% by 2028 [5][7]